Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Noel T. Willcutt"'
Autor:
Margaret N. Baker, F. Anthony Greco, Jeremey Levin, Jeffrey Patton, Paul V. McGuirt, Howard A. Burris, Noel T. Willcutt, John H. Barton, Suzanne F. Jones, John D. Hainsworth
Publikováno v:
The Oncologist. 7:444-450
Purpose. This phase I study was conducted to determine the dose-limiting toxicity (DLT), maximum-tolerated doses, and recommended phase II doses of the combination of weekly intravenous paclitaxel and oral eniluracil/5-fluorouracil (5-FU). Patients a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e58e7813b89981f06412365c06c51d2
https://doi.org/10.1634/theoncologist.7-5-444
https://doi.org/10.1634/theoncologist.7-5-444
Autor:
F. Anthony Greco, Noel T. Willcutt, Eric L. Raefsky, Aurelia F. Beschorner, Howard A. Burris, Suzanne F. Jones, Fernando T. Miranda, Victor G. Gian, Glyndon Kennerly, John D. Hainsworth
Publikováno v:
Cancer. 104(9)
BACKGROUND The current Phase I trial was conducted to determine the dose-limiting toxicity (DLT), maximum tolerated dose, and recommended Phase II dose of oral fixed-dose temozolomide when administered for 5 of every 7 days on a continuous basis. MET
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd6916a209e973d4a48663865509ea50
https://pubmed.ncbi.nlm.nih.gov/16134182
https://pubmed.ncbi.nlm.nih.gov/16134182
Autor:
Suzanne F, Jones, Victor G, Gian, F Anthony, Greco, Fernando T, Miranda, Dianna L, Shipley, Dana S, Thompson, John D, Hainsworth, Mitchell A, Toomey, Noel T, Willcutt, Howard A, Burris
Publikováno v:
Oncology (Williston Park, N.Y.). 17(5 Suppl 5)
This phase I study was conducted to determine the dose-limiting toxicity, maximum tolerated doses, and recommended phase II doses of the combination of irinotecan (CPT-11, Camptosar) and temozolomide (Temodar). Patients have received irinotecan and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9708a8fff18b09c34943b9e7b8f93ccb
https://pubmed.ncbi.nlm.nih.gov/12800606
https://pubmed.ncbi.nlm.nih.gov/12800606
Autor:
Suzanne F, Jones, Howard A, Burris, John D, Hainsworth, Denise A, Yardley, Eric A, Raefsky, Fernando T, Miranda, Michel E, Kuzur, Noel T, Willcutt, Melissa B, White, F Anthony, Greco
Publikováno v:
Oncology (Williston Park, N.Y.). 17(5 Suppl 5)
A phase I study of carboplatin (Paraplatin) administered in two different dosing schedules (single dose every 4 weeks and weekly dosing) in combination with weekly irinotecan (CPT-11, Camptosar) was conducted in patients with relapsed or refractory a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f7a7e9dea5b572c4471128194a467e3f
https://pubmed.ncbi.nlm.nih.gov/12800605
https://pubmed.ncbi.nlm.nih.gov/12800605
Autor:
Howard A. Burris, F. Anthony Greco, Jane Bramham, Sharon Calvert, Daniel C. Scullin, John D. Hainsworth, Noel T. Willcutt
Publikováno v:
Cancer investigation. 19(4)
The purpose of this study was to evaluate the activity of single-agent gemcitabine in previously treated patients with carcinoma of unknown primary site. Between January 1997 and October 1998, 39 patients were enrolled in this multicenter Phase II tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::676c0f4fafe3165b1d10116845868c1e
https://pubmed.ncbi.nlm.nih.gov/11405172
https://pubmed.ncbi.nlm.nih.gov/11405172
Autor:
Suzanne F. Jones, F. Anthony Greco, Victor G. Gian, Fernando T. Miranda, Eric L. Raefsky, John D. Hainsworth, Noel T. Willcutt, Aurelia F. Beschorner, Glyndon Kennerly, Howard A. Burris
Publikováno v:
Cancer (0008543X); Oct2005, Vol. 104 Issue 9, p1985-1991, 0p